

223. The method according to claim 220 further comprising a step of refolding said GDNF polypeptide to form a disulfide-bonded dimer.

224. The method according to claim 220 wherein said GDNF polypeptide is expressed by a bacterial host cell and is refolded to form a disulfide-bonded dimer.

225. The method according to claim 220 wherein the GDNF polypeptide produced is secreted by said host cell.

226. An expression vector comprising the nucleic acid of claim 183.

227. An isolated host cell comprising the expression vector of claim 226 and wherein said cell is capable of producing and secreting said GDNF polypeptide.

228. The host cell of claim 227 wherein said cell is selected from the group consisting of:

- (a) a microorganism;
- (b) an animal cell; and
- (c) a COS cell.

REMARKS

Claims 88-90, 94, 118-120, 124, 135, 137-140, 142, 150, 152, 154-157, 160, 165-171, and 175-177 were previously allowed. The claims that were pending in the case were either rewritten or cancelled (to remove duplicative claims) and then reordered and renumbered, at the Examiner's request to facilitate completion of the reopened examination. The amendments proposed herein are entirely formalistic in nature and are intended to place the case in suitable condition for allowance.

Claims 226 through 228 are newly added claims to this amendment. These claims were not previously presented to the Examiner. Applicants would like to discuss their inclusion into the final claims.

Applicants are sending under separate cover a hardcopy of this Draft Amendment, a revised Sequence Listing and a computer-readable form (CRF) thereof, and copies of some previous communications sent by Applicants to the Examiner. Recent discussions between Applicants and the Examiner have made it apparent that some of Applicant's submissions to the Patent and Trademark Office were not received by the Examiner. The revised Sequence Listing and CRF is being submitted in response to the Examiner's finding that the most recent Sequence Listing on file did not list separately the rat and human pre-pro GDNF amino acid sequences even though those sequences were discussed separately from their corresponding nucleic acid sequences. The Sequence Listing as revised provides a separate listing for the rat and human pre-pro GDNF amino acid sequences (i.e., SEQ ID NO:27 and 28, respectively). In addition, the revised Sequence Listing includes a correction to the polynucleotide sequence of SEQ ID NO:5. The correction amounts to a deletion of the "a" nucleotide at position 26 and the insertion of an "a" nucleotide after the "c" nucleotide at position 22. This correction results in a polynucleotide sequence that correctly encodes the first amino acid residue, Ser.

Applicants respectfully request that Examiner substitute the revised Sequence Listing provided herewith for the Sequence Listing currently on file. Applicants also respectfully request consideration of the new claims presented herein and passage of the case to issue.

Applicants' representative would appreciate the opportunity to talk with the Examiner, in person or by telephone, to discuss any remaining questions and facilitate the allowance of the application.

Respectfully submitted,

DRAFT

Please send all future correspondence to:
U.S. Patent Operations/RLS
Dept. 4300 M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

Robert L. Sharp
Attorney for Applicants
Registration No: 45,609
Phone: (805) 447-5992